Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as OMP-52M51
brontictuzumab · 3 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| Brontictuzumab and trifluridine/tipiracil | EXPERIMENTAL | Brontictuzumab will be administered per protocol and trifluridine/tipiracil per label. |
| OMP-52M51 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| brontictuzumab | DRUG | starting dose of 1.5mg/kg administered intravenously (IV) |
| trifluridine/tipiracil | DRUG | - |
| OMP-52M51 | DRUG | - |
Inclusion Criteria: * Histologically confirmed metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if KRAS wild-type, an anti-EGFR therapy * ECOG performance status 0 or 1 Exclusion Crit...
Top 20 of 80 competitors
Brontictuzumab is an investigational monoclonal antibody being studied for metastatic colorectal cancer. It has been evaluated in combination with chemotherapy in previously treated patients whose tumors are biomarker selected. It is not an approved therapy and remains in clinical development.
Brontictuzumab targets NOTCH1, a cell surface receptor in the NOTCH signaling pathway. It acts as an inhibitor of NOTCH1 signaling. Targeting this receptor is intended to interfere with tumor cell signaling in cancers that depend on NOTCH1 activity.
Brontictuzumab is being developed by Mereo BioPharma Group plc, which trades under the ticker MREO. The company holds the asset as part of its oncology pipeline.
Brontictuzumab is in Phase 1 clinical development. It is an investigational agent and has not been approved by the FDA for any indication. The completed Phase 1 study enrolled seven patients with metastatic colorectal cancer.
Brontictuzumab has been studied in one clinical trial, NCT03031691, titled A Study of Brontictuzumab With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer. That Phase 1 trial is completed, was conducted in the United States, and enrolled seven patients.
The Phase 1 trial of brontictuzumab, NCT03031691, was an uncontrolled, non-randomized, open-label study. It enrolled seven adults aged 18 years and older with previously treated metastatic colorectal cancer, and it did not use a placebo or comparator arm.